Cargando…

Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials

Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with a high initial response rate followed almost invariably by relapse. Here we report the pooled data from 2 studies, BGB-3111-AU-003 and BGB-3111-206, to explore the efficacy of zanubrutinib monotherapy in relapsed/refractory (R/R) MCL. A tot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Keshu, Zou, Dehui, Zhou, Jianfeng, Hu, Jianda, Yang, Haiyan, Zhang, Huilai, Ji, Jie, Xu, Wei, Jin, Jie, Lv, Fangfang, Feng, Ru, Gao, Sujun, Zhou, Daobin, Tam, Constantine S., Simpson, David, Wang, Michael, Phillips, Tycel J., Opat, Stephen, Huang, Zhiyue, Lu, Huafei, Song, Yuqin, Song, Yongping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518153/ https://www.ncbi.nlm.nih.gov/pubmed/34649571 http://dx.doi.org/10.1186/s13045-021-01174-3

Ejemplares similares

Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis
por: Song, Yuqin, et al.
Publicado: (2023)

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
por: Song, Yuqin, et al.
Publicado: (2023)

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
por: Song, Yuqin, et al.
Publicado: (2022)

Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
por: Tam, Constantine S., et al.
Publicado: (2022)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma
por: Yang, Haiyan, et al.
Publicado: (2022)

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
por: Xu, Wei, et al.
Publicado: (2020)

Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

Correction: Zanubrutinib: past, present, and future
por: Tam, Constantine S., et al.
Publicado: (2023)

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
por: An, Gang, et al.
Publicado: (2021)

Zanubrutinib for mantle cell lymphoma, Waldenström’s macroglobulinaemia
Publicado: (2021)

Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion
por: Tam, Constantine S., et al.
Publicado: (2020)

Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series
por: Zhang, Yan, et al.
Publicado: (2021)

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
por: Tam, Constantine S., et al.
Publicado: (2023)

Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
por: Alsuhebany, Nada, et al.
Publicado: (2023)

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
por: Opat, Stephen, et al.
Publicado: (2023)

Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome
por: Wong, Jonathan, et al.
Publicado: (2018)

Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia
por: Tam, Constantine, et al.
Publicado: (2023)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
por: Sawalha, Yazeed, et al.
Publicado: (2020)

P1136: FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Zhang, Huilai, et al.
Publicado: (2023)

Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum]
Publicado: (2020)

PB1922: THE FIRST REPORT OF REAL-WORLD OUTCOMES OF ZANUBRUTINIB MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Luo, Jing, et al.
Publicado: (2023)

P1089: ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA
por: Qu, Chang-Ju, et al.
Publicado: (2023)

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
por: Molica, Stefano, et al.
Publicado: (2023)

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma
por: Tatarczuch, Maciej, et al.
Publicado: (2023)

Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study
por: Cull, Gavin, et al.
Publicado: (2021)

P1242: ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR TREAT-NAIVE PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY
por: Zhang, Y., et al.
Publicado: (2022)

Simultaneous development of zanubrutinib in the USA and China
por: Li, Guanqiao, et al.
Publicado: (2020)

A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies
por: Song, Yuqin, et al.
Publicado: (2022)

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
por: Zhang, Yuchen, et al.
Publicado: (2022)

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
por: Hillmen, Peter, et al.
Publicado: (2023)

The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
por: Opat, Stephen, et al.
Publicado: (2021)

Zanubrutinib in lymphoproliferative disorders: a comprehensive review
por: Muñoz, Javier, et al.
Publicado: (2022)

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES
por: Tam, Constantine, et al.
Publicado: (2023)

Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation
por: Li, Wenqi, et al.
Publicado: (2023)

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
por: Song, Yuqin, et al.
Publicado: (2019)

Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022;6(4):1296-1308.
Publicado: (2022)

Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
por: Deshpande, Anagha, et al.
Publicado: (2022)

Disseminated fungal infection in a patient receiving zanubrutinib
por: Walsh, Madalyn, et al.
Publicado: (2023)

MiRNA-223-3p Affects Mantle Cell Lymphoma Development by Regulating the CHUK/NF-ƘB2 Signaling Pathway
por: Yuan, Jingjing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ftnnhjcn19i662mc3t3d6vnoqo